SAB Biotherapeutics (SABS) EBITDA Margin Growth (1y) (2022 - 2024)
Powered by 
Analysis
SAB Biotherapeutics (SABS) EBITDA Margin Growth (1y) (2022 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 7,666.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1,238.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2,002.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -1,651.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 29,091.00 |
| 10 | SAB Biotherapeutics | 296.68 Mn | 296.68 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -253,836.00 |
| Jun 30, 2024 | 369,644.00 |
| Mar 31, 2024 | 6,789.00 |
| Dec 31, 2023 | -582,416.00 |
| Sep 30, 2023 | -20,251.00 |
| Jun 30, 2023 | -747,037.00 |
| Mar 31, 2023 | -121,696.00 |
| Dec 31, 2022 | -29,733.00 |
| Sep 30, 2022 | -19,031.00 |
| Jun 30, 2022 | -8,726.00 |
| Mar 31, 2022 | -6,164.00 |